Alexander Volkov/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The psychedelics industry has ramped up over the past year as institutional investors entered and several companies have gone public.
Insider identified the top 14 startups that are working to turn psychedelics into approved medicines for conditions like depression, opioid use disorder, and anxiety.
To put together this article, we reached out to companies on our list from last year, used data provided by PitchBook, and talked to VCs in the space.
2020 was a booming year for the psychedelics industry.
Money swept through the private side of the space as big names like Atai Life Sciences closed record-breaking rounds of funding and more companies entered, hoping to take part in what could become a $100 billion market, according to a May 2020 report from Canaccord Genuity.
Beckley Psytech This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
UK-based psychedelics company Beckley Psytech just closed an $18.6 million funding round, backed by investment firms Noetic Psychedelic Fund and Bail Capital.
Beckley Psytech s upcoming clinical trials will be focused on researching the synthetic compound 5-MeO-DMT, a psychedelic agent found naturally in the Sonoran Desert toad.
The company says it s preparing to test other compounds as well.
Cosmo Feilding Mellen was involved in the world of psychedelics long before the compounds started to become mainstream.
Feilding Mellen is the cofounder and CEO of UK-based psychedelics company Beckley Psytech, but his family and his mother Amanda Feilding, in particular has been involved in the scientific studies around psychedelics since 1998. That s the year Feilding started the Beckley Foundation, a n